Needham & Company downgraded Intermolecular (NASDAQ: IMI) from Buy to Hold on decreased revenue expectations.

"We are downgrading IMI ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE